ArticleCurrent pharmacology reports2017
The Opportunities of Metabolomics in Drug Safety Evaluation.
Article in Current pharmacology reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- Plant Metabolomics: The Future of Anticancer Drug Discovery.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Study on chemical constituents and antioxidant activities ofFrontiers in plant science · 2024Article
- NMR-Based Metabolomics to Evaluate Individual Response to Treatments.Handbook of experimental pharmacology · 2023Article
- Roles of Cofactors in Drug-Induced Liver Injury: Drug Metabolism and Beyond.Drug metabolism and disposition: the biological fate of chemicals · 2022Review
- Integration of Transcriptomics Data and Metabolomic Data Using Biomedical Literature Mining and Pathway Analysis.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Metabolic profiling of liver and faeces in mice infected with echinococcosis.Parasites & vectors · 2021Article
- Approaches in metabolomics for regulatory toxicology applications.The Analyst · 2021Review
- Deciphering the mechanism of action of antitubercular compounds with metabolomics.Computational and structural biotechnology journal · 2021Review
- An omics perspective on drug target discovery platforms.Briefings in bioinformatics · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although safety of drug candidates is carefully monitored in preclinical and clinical studies using a variety of approaches, drug toxicity may still occur in clinical practice. Therefore, novel approaches are needed to complement the current drug safety evaluation system. Metabolomics comprehensively analyzes the metabolites altered by drug exposure, which can therefore be used to profile drug metabolism, endobiotic metabolism, and drug-microbiota interactions. The information from metabolomic analysis can be used to determine the off-targets of a drug candidate, and thus provide a mechanistic understanding of drug toxicity. We herein discuss the opportunities of metabolomics in drug safety evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.